# Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

> **NCT06464614** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Henan University of Science and Technology** · enrollment: 54 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Apatinib
- **DRUG:** Investigator chosen chemotherapy (ICC)
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT06464614
- **Lead sponsor:** The First Affiliated Hospital of Henan University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-15
- **Primary completion:** 2025-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06464614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06464614, "Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06464614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*